Your session is about to expire
← Back to Search
Nebulized Scopolamine for Motion Sickness
Study Summary
This trial is testing a nebulizer that goes up the nose to see if it is a better way to give anti-motion sickness medication.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 1 trial • 27 Patients • NCT02051335Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I am allergic to scopolamine or similar medications.I have a significant condition like Crohn's, asthma, or glaucoma.My kidney and liver functions are normal.You have a normal neurological exam, which means your brain and nervous system are functioning properly.I have not donated blood or had significant blood loss in the last 30 days.I am between 21 and 49 years old., is required for all study participants
The study participants need to be in good health, as determined by their verbal medical history.I have not had major surgery in the last 3 months.I have not had nasal or sinus surgery in the last 90 days.I have wheezing or other breathing issues.I haven't had a cold, severe allergies, or sinus infections in the last month.I have a severe blockage in one nostril due to a deviated septum.I am unable to give consent by myself.My weight is normal for my height.I am currently using nasal spray medication.I am either male or female.My kidney and liver functions are normal.I am between 21 and 49 years old.I am either male or female.My weight is normal for my height.I am either male or female.I am between 21 and 49 years old.
- Group 1: Chair
- Group 2: Pharmacokinetic
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the minimum age threshold for this clinical trial eighteen years or older?
"This clinical trial has a designated age range for enrollment, where patients must be at least 21 years of age and no more than 49."
How many people are currently involved in this research experiment?
"This trial has stopped recruiting participants; it was listed as of January 24th 2022 and last updated on October 22nd 2022. In case you're looking for other clinical trials, there are 5 studies currently enrolling patients with airsickness and a further 7 requiring volunteers to test Scopolamine's efficacy."
Are participants being accepted for this trial at present?
"The data on clinicaltrials.gov shows that this medical research project, initially posted in January 24th 2022, is no longer seeking participants. However, it should be noted twelve other trials are still actively enrolling at the present moment."
What can you tell me regarding prior experiments with Scopolamine?
"Currently, 7 studies are exploring the potential of Scopolamine as a medication. One is in its final Phase 3 testing stage while 16 medical sites across Lebanon, New hampshire are actively running trials on this drug."
What therapeutic purposes does Scopolamine typically serve?
"Scopolamine has been frequently utilized to treat nausea, and also preanesthetic medication, anesthetic premedication therapy, motion sickness."
Could I be a candidate for this research endeavor?
"In order to be accepted into this research program, prospective participants must suffer from airsickness and belong in the 21 to 49-year age range. The total recruitment pool for this trial consists of 30 individuals."
Are there any risks associated with Scopolamine use?
"Scopolamine's safety has only been studied to a limited degree, thus it was rated 1 on our scale. This reflects its status as an experimental medication in early-stage trials."
Share this study with friends
Copy Link
Messenger